AN2 Therapeutics Inc. (ANTX)
NASDAQ: ANTX
· Real-Time Price · USD
1.21
0.06 (5.22%)
At close: May 29, 2025, 3:59 PM
1.22
0.83%
After-hours: May 29, 2025, 07:16 PM EDT
5.22% (1D)
| Bid | 1.09 |
| Market Cap | 36.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.35M |
| EPS (ttm) | -1.51 |
| PE Ratio (ttm) | -0.8 |
| Forward PE | -0.88 |
| Analyst | Buy |
| Ask | 1.25 |
| Volume | 85,811 |
| Avg. Volume (20D) | 147,075 |
| Open | 1.13 |
| Previous Close | 1.15 |
| Day's Range | 1.12 - 1.22 |
| 52-Week Range | 0.87 - 3.07 |
| Beta | 0.01 |
About ANTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+0%
AN2 Therapeutics shares are trading lower after th...
Unlock content with
Pro Subscription
9 months ago
-60.98%
AN2 Therapeutics shares are trading lower after the company announced that it will discontinue its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
2 months ago · businesswire.com
AN2 Therapeutics to Present at Leerink Partners Global Healthcare ConferenceMENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c...